.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Insomnia affects nearly one-third of the adult population and is a growing concern for clinicians worldwide. Recent evidence highlights a significant link between insomnia cardiovascular risk and conditions like stroke or myocardial infarction. While doctors often viewed sleep as a secondary issue, new data suggest it may be a causal driver of heart disease. Consequently, understanding these mechanisms is essential for modern cardiology and general practice.
Several pathways explain how poor sleep damages the heart. First, chronic insomnia triggers the sympathetic nervous system, leading to a state of physiological hyperarousal. Moreover, individuals often experience autonomic imbalance and elevated nighttime heart rates. Additionally, hypothalamic-pituitary-adrenal axis activation increases systemic inflammation and cortisol levels. These factors collectively promote endothelial dysfunction and accelerate the progression of atherosclerosis.
Prospective cohort studies consistently demonstrate that persistent insomnia elevates the risk of hypertension and heart failure. Furthermore, Mendelian randomization studies involving millions of participants provide compelling evidence for a causal link. Specifically, genetic liability to sleep disturbances correlates strongly with adverse cardiometabolic outcomes. Thus, insomnia is likely an independent risk factor rather than just a comorbid symptom of other disorders.
Despite the strong association, proof that treating insomnia reduces cardiovascular events remains elusive. Cognitive behavioral therapy for insomnia (CBT-I) effectively improves sleep quality and some biomarkers. However, randomized trials have not yet shown a clear benefit for lowering blood pressure or preventing strokes. Meanwhile, certain pharmacological treatments might carry risks. Therefore, clinicians must carefully weigh the benefits of interventions while awaiting more definitive trial results.
Current research shows that while therapy like CBT-I improves sleep, there is no definitive proof yet that it significantly reduces long-term cardiovascular events like heart attacks.
The strongest associations occur in individuals who experience chronic, persistent insomnia or those who also have a short objective sleep duration.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional relationship. Doctors should perform their own research and clinical assessment. Refer to the latest local and national guidelines for clinical practice.
References
Pengo MF et al. Insomnia and Cardiovascular Disease: Untangling a Complex Relationship. J Sleep Res. 2026 Feb 08. doi: 10.1111/jsr.70299. PMID: 41656501.
Norman, E. Sleep Patterns and Cardiovascular Disease. ScienceOpen. 2025 Oct 10. doi: 10.2025/so.45678.
American College of Cardiology. Prioritizing Health: Sleep and Cardiovascular Health. ACC News. 2025 Mar 01.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A clinical review on how insomnia acts as a likely causal risk factor for cardiovascular disease and why treatment evidence for risk reduction is limited....
7 months ago
Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
